A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer.
Phase 2
- Conditions
- Stage IVB, recurrent or persistant cervical cancer
- Registration Number
- JPRN-UMIN000026063
- Lead Sponsor
- Japan Gynecologic Oncology Group:JGOG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient who has received any cheotherapy except for CCRT 2.Patient with perforation of the digestive tract and severe fistula within 6 months before registration 3.Patient with a history of hypersensitivity to the drug used in combination to bevacizumab 4.Patient with active infection at registration 5. Patient with uncontrolled hypertension at registration 6.Patient suspected or diagnosed as arterial thromboembolism (cerebral infarction, myocardial infarction, etc.) at registration 7.Patient who is judged inappropriate to participate in this study by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method